(TheNewswire)
VANCOUVER, BC – TheNewswire- August 17, 2022 - AREV LIFE SCIENCES GLOBALCORP. (CSE:AREV) (CNSX:AREV.CN) (OTC:AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation AREV Life Sciences Global Corporation announcesthe appointment of Sateesh Apte MD to the Scientific Advisory Board(the “SAB”) of AREV.
AREV Life Sciences announced the appointment of SateeshApte MD to its Scientific Advisory Board, as part of the current scaleup for launching clinical studies of SUSTAINN ™ for treating Serious Acute Malnutrition in Low& Middle Income Countries. “LMIC”
Dr Apte ’ sexpertise in neurological pathogenesis will complementAREV’ s focus onpositioning SUSTAINN ™ toaddress the cognitive preservation of children experiencing seriousacute malnutrition, which causes brain damage in millions of malnourished children a year. Said Mike Withrow,CEO of AREV Life Sciences Dr.Apte’ s appointment to the SAB of AREV is acritical step in successfully designing our studies to demonstrate theclinical value of SUSTAINN in treating SAM.
Dr. Apte specializes in neurology and has an extensivebackground in research, teaching and consulting in the field ofneurological sciences. Dr. Apte ’ s graduate training was at Haffkine Institute in Mumbai,India, The Pasteur Institute in Paris, France, at Harvard MedicalSchool in Boston and at Stanford University in California. Hisprofessional appointments have included active staff positions at theVA Medical Center and Valley Memorial Hospital in Livermore, CA;ValleyCare Medical Center in Pleasanton, CA, and directorships withPainCare Medical Clinic, and the Sleep Disorders Center in San Ramonand Pleasanton, CA. He most recently served as President and CEO ofNorthern California Physicians Associates, Inc. and Alpha MedicalGroup, Inc. (1986-1992) He served as Presidentand CEO of ImmunoScience, Inc. in Pleasanton, CA until 2019. Dr. Aptehas authored and co-authored a number of articles for medical journalsand has several publications pending.
Dr Apte stated “ I am very excited to join the AREV SAB as the companycommences some of the most important studies in public health formillions of children affected by SAM. The research to attribute thetherapeutic effect of SUSTAINN ™ promises to be a groundbreaking advance in addressing thisleading cause of pediatric mortality during a global famine, that isexacerbating the burden of infectious diseases in developing nations,which has serious implications for global public health andsecurity ”.
Dr Apte ’ sappointment directly follows a series of meetings at AIDS 2022 withAREV ’ s corporateleadership, involving representatives of UNAIDS, the World FoodProgram, USAID, The WHO, NIAID, The MHRP, The Global Fund for AIDS, TBand Malaria, PEPFAR to review concept sheet development of initialstudies of SUSTAINN being planned for the 1 st Q of2023.
Further, the Company is pleased to announce thatt he Company has issued 100,000 stock options toDirectors, Officers and Consultants of the Company at a price of $0.12for a period of 5 years from the issuance dated. These options willvest immediately.
About SUSTAINN™
Being developed in collaboration with the RichardsonCenter for FOOD TECHNOLOGIES AND RESEARCH and leadership atOSU ’ s Linus PaulingInstitute. SUSTAINN™ is a next generation Ready to Use TherapeuticFood designed to provide superior clinical value for patientspresenting SAM. SUSTAINN™ is intended to address the dysbiosis,enteropathy and loss of intestinal microbiome which characterizes SAMand the long term cognitive degeneration of SAM patients.
For further information, contact Mike Withrow,arevlifesciences@gmail.com 778-929-6536. For more information visitwww.arevlifesciences.com.
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Life Sciences GlobalCorp.
The Company is a fully integrated enterprise withcompetencies in: 1) extraction of compounds for consumption andtopical use. 2) Clinical Nutrition and 3) A technology platform calledMedicine Merchant. The Company produces ingredients and formulatesexclusive therapeutic interventions with plans to deliver innovationin clinical nutrition, proprietary supplements, topicals and rationaldrug design, based on science. The Company’s business model leverages its core competency of extraction to produceingredients and compounds for its pipeline of products. The Companycontinues in the product development and pre-commercializationstage.
AREV is dedicated to designing and deliveringinnovation in rational drug design, driven by presenting globalepidemiological characteristics of multiple challenges tointernational human and animal health. AREV is a member of bothBIOTECanada and The Biotechnology Innovation Organization (BIO).
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITSREGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITYFOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in policies ofthe CSE) accepts responsibility for the adequacy or accuracy of thisrelease. This news release may include forward-looking statements thatare subject to risks and uncertainties. All statements within, otherthan statements of historical fact, are to be considered forwardlooking. Although the Company believes the expectations expressed insuch forward looking statements are based on reasonable assumptions,such statements are not guarantees of future performance and actualresults or developments may differ materially from those inforward-looking statements. Factors that could cause actual results todiffer materially from those in forward-looking statements includemarket prices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as required
under the applicable laws. This press release containsforward-looking statements. The use of any of the words"anticipate", "continue", "estimate","expect", "may", "will","project", "should", "believe" andsimilar expressions are intended to identify forward-lookingstatements. Although the Company believes that the expectations andassumptions on which the forward-looking statements are based arereasonable, undue reliance should not be placed on the forward-lookingstatements because the Company can give no assurance that they willprove to be correct. Since forward-looking statements
address future events and conditions, by their verynature they involve inherent risks and uncertainties. These statementsspeak only as of the date of this press release. Actual results coulddiffer materially from those currently anticipated due to a number offactors and risks various risk factors discussed in theCompany’ s Management ’sDiscussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2022 TheNewswire - All rights reserved.